Recent Updates
Recently added Catalysts

lorundrostat

Phase 3

Hypertension | Small molecule | Cardiovascular |Mineralys Therapeutics, Inc.|Last Updated: Jul 17, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindCONTROLLEDDMC
Total Trials3
Total Enrollment2,444
FDA Designations
No designations recorded
Clinical trial landscape

lorundrostat · 4 trials · 2 indications

Phase 3 2Phase 2 2
NCT06153693Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant HypertensionHypertension
COMPLETED1,083 Analytics
NCT05968430Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With HypertensionHypertension
ACTIVE NOT_RECRUITING1,076 Analytics
PHASE3COMPLETED
Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension
HypertensionUnlock trial analytics
PHASE3ACTIVE NOT_RECRUITING
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
HypertensionUnlock trial analytics
Study Endpoints
Primary Endpoints
Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo
Week 6
Change from MLS-101-301 baseline automated office blood pressure
Week 36

Change from MLS-101-301 baseline automated office blood pressure (AOBP) systolic blood pressure (SBP) at MLS-101-901 Week 36 in subjects who were enrolled in the lorundrostat arms of MLS-101-301 and were not assigned to the placebo arm of the MLS-101-901 RTW substudy

Change at MLS-101-901 Week 16 (RTW Week 4) from MLS 101-901 Week 12 (RTW substudy baseline) in AOBP SBP in subjects enrolled in RTW
Week 16
Placebo-adjusted Change From Baseline in AHI at Week 4
Baseline, Week 4
Change in 24-hour average ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP)
Baseline (Randomization) to Week 12
Secondary Endpoints
Proportion of subjects with AOBP SBP <130 mmHg at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo
Week 6
Change from baseline in AOBP SBP at Week 12 in subjects randomized to lorundrostat 50 mg QD with escalation to lorundrostat 100 mg QD compared to subjects randomized to placebo
Week 12
Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 2 prescribed AHT medications
Week 6
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PlaceboPLACEBO_COMPARATORPlacebo once daily (QD) for 12 weeks
Dose 1EXPERIMENTAL50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
Dose 2EXPERIMENTAL50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
Open-Label ArmEXPERIMENTALlorundrostat once daily for 52 weeks depending on when the subject enrolled
RTW SubstudyEXPERIMENTALlorundrostat or placebo once daily for 4 weeks starting at week 12, in the double-blind randomized treatment withdrawal substudy Optional for subjects from the MLS-101-301 parent study only
Optional Continuation PeriodEXPERIMENTALlorundrostat once daily from week 52 or until marketing authorization or early termination of the trial by the sponsor
Sequence 1: Lorundrostat then PlaceboEXPERIMENTAL -
Sequence 2: Placebo then LorundrostatEXPERIMENTAL -
Interventions
NameTypeDescription
PlaceboDRUGPlacebo once daily (QD) for 12 weeks
lorundrostat Dose 1DRUG50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks
lorundrostat Dose 2DRUG50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria
lorundrostatDRUGTablet, administered orally
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites184

Inclusion Criteria: 1. At least 18 years of age at the time of signing the informed consent form (ICF) 2. At Screening and Randomization: AOBP SBP of ≥135 and ≤180 mmHg plus AOBP DBP of ≥65 and ≤110 mmHg, or AOBP DBP of ≥90 and ≤110 mmHg 3. Taking between 2 and 5 AHT medications, 4. History of hype...

Countries:United StatesAustraliaBulgariaCanadaFranceGermanyItalyNetherlandsPolandPuerto RicoRomaniaSpainUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
MEDIUMJul 17, 2026NCT05968430Completion: 2026-12 → 2027-05
MEDIUMJul 17, 2026NCT05968430Completion: 2026-12 → 2027-05
MEDIUMJun 1, 2026NCT06153693TRIAL_REMOVED: changed
MEDIUMJun 1, 2026NCT06153693TRIAL_REMOVED: changed
MEDIUMJun 1, 2026NCT06153693TRIAL_REMOVED: changed
LOWMay 26, 2026NCT05968430primaryCompletionDate: changed
LOWMay 24, 2026NCT05968430studyFirstPostDate: changed